Posters

      Modeling the Population Years of Life Saved in Japan, Italy, Singapore, And The U.S. by Introducing a Reduced-Risk Product

      Djurdjevic, S.; Weitkunat, R.; Baker, G.; Lüdicke, F.; Silva, N. M.

      Conference date
      May 21, 2019
      Conference name
      ISPOR US
      Link to more information
      Topic
      Summary

      Objectives: The objective of the present modeling was to assess the population health impact of introducing Reduced-Risk Products (RRP) in countries where such products are already, or may be, marketed. The modeling reported here addresses the IQOS® heat-not-burn tobacco product in four countries: Japan, Italy, Singapore, and the U.S. Methods: The Population Health Impact Model was used to estimate the reduction of smoking attributable deaths and years of life saved (YLS) following the introduction of IQOS. The model predicts YLS due to lung cancer, ischemic heart disease, stroke, and chronic obstructive pulmonary disease by considering two scenarios: a null scenario without IQOS and an RRP scenario with IQOS. Modeling predictions are based on hypothetical Japanese, Italian, Singaporean, and American populations for the period of 1990–2010. Simulations were run to predict YLS by introducing IQOS in those countries, from data available in markets where IQOS is present. Results: The predicted YLS over the 20-year simulation period are presented following the introduction of IQOS in the U.S. and Italy at 17% uptake after 10 years (15% exclusive IQOS use and 2% dual use) and Japan and Singapore at 55% uptake (48% exclusive IQOS and other RRP use and 7% dual use). The modeling assumes that a majority of RRP uptake comes from current adult smokers switching to IQOS and that the effective dose of IQOS is 20% of that of cigarette smoking. The results demonstrate 0.96 million YLS for Japan, 0.11 million for Italy, 0.03 million for Singapore, and 1 million for the U.S. over the 20-year period. Conclusions: Modeling the population YLS upon introducing IQOS allows for a comprehensive assessment of the population health impact. The results demonstrate that an RRP can further reduce the overall population health impact in four countries with different smoking habits and RRP uptake, in addition to existing tobacco control efforts.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.